Analysis of health-related quality of life and muscle impairment in individuals with amyotrophic lateral sclerosis using the medical outcome survey and the tufts quantitative neuromuscular exam

Archives of Physical Medicine and Rehabilitation

Volumn 79, Issue 7, 1998, Pages 855-862

  Shields, Richard K ^a,b   Ruhland, Janet L ^a   Ross, Mark A ^a   Saehler, Margaret M ^a   Smith, Kent B ^a   Heffner, Marta L ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL ARTICLE; CORRELATION FUNCTION; DISEASE COURSE; FEMALE; FUNCTIONAL ASSESSMENT; HEALTH SURVEY; HUMAN; HUMAN TISSUE; MALE; MUSCLE FORCE; MUSCLE STRENGTH; NEUROMUSCULAR FUNCTION; PATIENT CODING; QUALITY OF LIFE; RELIABILITY;

EID: 0031830464     PISSN: 00039993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-9993(98)90370-7     Document Type: Article

References (34)

1. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Brain 1995;118:707-19.
2. McDonald ER, Wiedenfeld SA, Hillel A, Carpenter CL, Walker RA. Survival in amyotrophic lateral sclerosis. The role of psychological factors. Arch Neurol 1994;51:17-23.
3. Hunter MD, Robinson IC, Neilson S. The functional and psychological status of patients with amyotrophic lateral sclerosis: some implications for rehabilitation. Disabil Rehabil 1993;15:119-26.
4. Norris FH, Calanchini PR, Fallat RJ, Panchari S, Jewett B. The administration of guanidine in amyotrophic lateral sclerosis. Neurology 1974;244:721-8.
5. Olarte MR. Therapeutic trials in amyotrophic lateral sclerosis. Adv Neurol 1982;555-7.
6. Andres PL, Hedlund W, Finison L, Conlon T, Felmus M, Munsat TL. Quantitative motor assessment in amyotrophic lateral sclerosis. Neurology 1986;36:937-41.
7. Appel V, Stewart SS, Smith G, Appel SH. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 1987;22:328-33.
8. Eisen A, Schulzer M, MacNeil M, Pant B, Mak E. Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve 1993;16:27-32.
9. Pradas J, Finison L, Andres PL, Thornell B, Hollander D, Munsat TL. The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials. Neurology 1993;43: 751-5.
10. Munsat TL, Andres PL, Finison L, Conlon T, Thibodeau L. The natural history of motoneuron loss in amyotrophic lateral sclerosis. Neurology 1988;38:409-31.
11. Bensimon G, Lacombley L, Meininger V. A controlled trial of Riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330: 585-91.
12. Bocker FM, Seibold I, Neundorfer B. Physical disability and depression in patients with advanced amyotrophic lateral sclerosis (ALS). Fortsch Neurol Psychiatr 1990;58:224-36.
13. Rubenstein LV, Calkins DR, Greenfield S, Jette AM, Meenan RF, Nevins MA, et al. Health status assessment for elderly patients: report of the Society of General Internal Medicine Task Force on Health Assessment. J Am Geriatr Soc 1988;37:562-9.
14. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey manual and interpretation guide. Boston (MA): The Health Institute, New England Medical Center; 1993.
15. Stewart AL, Greenfield S, Hays RD, Wells K, Rogers WH, Berry SD, et al. Functional status and well being of patients with chronic conditions. JAMA 1989;262:907-13.
16. McHorney CA, Ware JE, Rogers W, Raczek AE, Lu JF. The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Med Care 1992;30: MS253-65.
17. McHorney CA, Ware JE, Raczek AE. The MOS 36-item short-form health survey (SF-36): II: psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-63.
18. McHorney CA, Ware JE, Rachel Lu JF, Sherbourne CD. The MOS 36-item short form health survey (SF-36): III: tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:40-66.
19. Enloe LJ, Shields RK. Evaluation of health related quality of life in individuals with vestibular disease using a disease specific and general outcome measure. Phys Ther 1997;77:890-903.
20. Ruhland JL, Shields RK. The efficacy of a home exercise program on impairment and health related quality of life in persons with chronic peripheral neuropathy. Phys Ther 1997;77:1021-4.
21. Shields RK, Ruhland JL, Ross M. A descriptive study of patients with amyotrophic lateral sclerosis (ALS) using the Tufts Quantitative Neuromuscular Exam (TQNE) and the Medical Outcomes Study Short Form Health Survey (SF-36) [abstract]. Phys Ther 1996;76 Suppl:S32.
22. World Federation of Neurology Research Committee on Neuromuscular Disease. Classification of neuromuscular diseases. J Neurol Sci 1988;86:333-60.
23. Andres PL, Finison LJ, Conlon T, Thibodeau LM, Munsat TL. Use of composite scores (megascores) to measure deficit in amyotrofic lateral sclerosis. Neurology 1988;38:405-8.
24. Bradley WG, Hedlund W, Cooper C, Desousa GJ, Gabbai A, Mora JS, et al. A double-blind controlled trial of bovine brain gangliosides (cronassial). Neurology 1984;34:1079-82.
25. Smith RA, Melmed S, Sherman B, Frane J, Munsat TL, Festoff BW. Recombinant growth hormone treatment of amyolateral sclerosis. Muscle Nerve 1993;16:624-33.
26. Keleman J, Hedlund W, Murray-Douglas P, Munsat TL. Lecithin is not effective in amyotrophic lateral sclerosis. Neurology 1982;32: 315-6.
27. Munsat TL, Easterday CS, Levy S, Wolff SM, Hiatt R. Amantadine and quanedine are ineffective in ALS. Neurology 1981;31:1054-5.
28. Munsat TL, Taft J, Kasdon D. Intrathecal infusion of thyrotropin-releasing hormone (TRH) in amyotrophic lateral sclerosis. Neurol Clin 1987;5:159-70.
29. Festoff RA, Smith S, Melmed J, Frane B, Sherman B, Finson R, et al. Tufts Quantitative Neuromuscular Examination and amyotrophic lateral sclerosis trials in the recombinant age. Ann Neurol 1988;24:138-9.
30. Munsat TL, Taft J, Jackson IM, Andres PL, Hollander D, Skerry L, et al. Intrathecal thyrotropin releasing hormone does not alter the progressive course of ALS: experience with an intrathecal drug delivery system. Neurology 1992;42:1049-56.
31. Shrout PE, Fleiss JL. Intraclass correlation: uses in assessing rate reliability. Psychol Bull 1979;86:420-8.
32. Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chron Dis 1987;40:171-8.
33. Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials 1981;2:93-113.
34. Jette DU, Downing J. Health status of individuals entering a cardiac rehabilitation program as measured by the Medical Outcomes Study 36-Item Short Form Survey (SF-36). Phys Ther 1994;74:521-7.